Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.58 |
| ▸ | GLA | P06280 | 1/20 | 0.58 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | MMP9 | P14780 | 3/20 | 0.44 |
| ▸ | MMP2 | P08253 | 2/20 | 0.44 |
| ▸ | MMP8 | P22894 | 2/20 | 0.44 |
| ▸ | MMP13 | P45452 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | MMP1 | P03956 | 1/20 | 0.44 |
| ▸ | MMP3 | P08254 | 1/20 | 0.44 |
| ▸ | CMA1 | P23946 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30020202 | 0.87 | GLA (0.55) | NPSR1GLATLR9MMP9SMN1; SMN2 | |
| SCHEMBL19806741 | 0.83 | DAO (0.50) | NPSR1GLAHSD17B10MMP9MMP2 | |
| SCHEMBL9402139 | 0.83 | NPSR1 (0.51) | NPSR1GLATLR9HSD17B10MMP9 | |
| SCHEMBL13045114 | 0.83 | DAO (0.43) | NPSR1GLAHSD17B10ALDH1A1MAPT | |
| SCHEMBL2673003 | 0.81 | CMA1 (0.49) | MEN1KMT2ACMA1 | |
| SCHEMBL6380741 | 0.81 | NPSR1 (0.47) | NPSR1GLAMMP9MMP2MMP8 | |
| SCHEMBL30019852 | 0.79 | MAPT (0.60) | GLAHSD17B10MEN1ALDH1A1MAPT | |
| SCHEMBL18025766 | 0.79 | GSK3B (0.68) | NPSR1GLAHSD17B10MMP9ALDH1A1 | |
| SCHEMBL13044844 | 0.77 | HRH3 (0.55) | SMN1; SMN2ALDH1A1MAPTKMT2A | |
| SCHEMBL30019695 | 0.77 | ALDH1A1 (0.71) | NPSR1GLAHSD17B10MMP9SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022245120-A1 | NOVEL COMPOUND AND COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT FOR INHIBITING BIOFILM FORMATION OR VIRULENCE OF PATHOGENIC MICROORGANISM | 부산대학교 산학협력단 | 2022-11-24 | — | — | WO | claimed |
| WO-2022245120-A1 | NOVEL COMPOUND AND COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT FOR INHIBITING BIOFILM FORMATION OR VIRULENCE OF PATHOGENIC MICROORGANISM | 부산대학교 산학협력단 | 2022-11-24 | — | — | WO | disclosed |
| US-20200038306-A1 | BARBITURIC ACID DERIVATIVES AS SELF-TANNING SUBSTANCES | MERCK PATENT GMBH (DE) | 2020-02-06 | — | — | US | disclosed |
| US-20200038306-A1 | BARBITURIC ACID DERIVATIVES AS SELF-TANNING SUBSTANCES | MERCK PATENT GMBH (DE) | 2020-02-06 | — | — | US | disclosed |
| EP-3522863-A1 | BARBITURIC ACID DERIVATIVES AS SELF-TANNING SUBSTANCES | Merck Patent GmbH (DE) | 2019-08-14 | — | — | EP | disclosed |
| WO-2018065359-A1 | BARBITURIC ACID DERIVATIVES AS SELF-TANNING SUBSTANCES | MERCK PATENT GMBH (DE) | 2018-04-12 | — | — | WO | disclosed |
| EP-3148983-A1 | N-HYDROXYLAMINO-BARBITURIC ACID DERIVATIVES AS NITROXYL DONORS | The Johns Hopkins University (US) | 2017-04-05 | — | — | EP | disclosed |
| US-9464061-B2 | N-hydroxylamino-barbituric acid derivatives | THE JOHNS HOPKINS UNIVERSITY (US) | 2016-10-11 | — | — | US | disclosed |
| US-20160060229-A1 | N-HYDROXYLAMINO-BARBITURIC ACID DERIVATIVES | NATIONAL SCIENCE FOUNDATION | 2016-03-03 | — | — | US | disclosed |
| WO-2015183838-A1 | N-HYDROXYLAMINO-BARBITURIC ACID DERIVATIVES AS NITROXYL DONORS | THE JOHNS HOPKINS UNIVERSITY (US) | 2015-12-03 | — | — | WO | disclosed |
| US-8173664-B2 | Modified pyrimidine glucocorticoid receptor modulators | CORCEPT THERAPEUTICS, INC. (US) | 2012-05-08 | — | — | US | disclosed |
| WO-2010136804-A1 | PYRIMIDINE DERIVATIVES FOR USE AS ANTIBIOTICS | ASTON UNIVERSITY (GB) | 2010-12-02 | — | — | WO | disclosed |
| EP-1778236-B1 | MODIFIED PYRIMIDINE GLUCOCORTICOID RECEPTOR MODULATORS | CORCEPT THERAPEUTICS INC (US) | 2010-07-14 | — | — | EP | disclosed |
| US-20090275600-A1 | MODIFIED PYRIMIDINE GLUCOCORTICOID RECEPTOR MODULATORS | CORCEPT THERAPEUTICS, INC. (US) | 2009-11-05 | — | — | US | disclosed |
| US-7576076-B2 | Modified pyrimidine glucocorticoid receptor modulators | CORCEPT THERAPEUTICS, INC. (US) | 2009-08-18 | — | — | US | disclosed |
| EP-1778236-A1 | MODIFIED PYRIMIDINE GLUCOCORTICOID RECEPTOR MODULATORS | Corcept Therapeutics, Inc. (US) | 2007-05-02 | — | — | EP | disclosed |
| WO-2006014394-A1 | MODIFIED PYRIMIDINE GLUCOCORTICOID RECEPTOR MODULATORS | CORCEPT THERAPEUTICS, INC. (US) | 2006-02-09 | — | — | WO | disclosed |
| US-20060025405-A1 | Modified pyrimidine glucocorticoid receptor modulators | CORCEPT THERAPEUTICS, INC. (US) | 2006-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060025405-A1 | Modified pyrimidine glucocorticoid receptor modulators | NR3C1, NR3C2, TYMS | NPSR1 1453/4885GLA 4334/4885TLR9 876/4885 |
| US-20200038306-A1 | BARBITURIC ACID DERIVATIVES AS SELF-TANNING SUBSTANCES | TYR, SLC6A1, GABBR1 | NPSR1 1250/4885GLA 469/4885TLR9 4331/4885 |
| US-20090275600-A1 | MODIFIED PYRIMIDINE GLUCOCORTICOID RECEPTOR MODULATORS | NR3C1, NR3C2, TYMS | NPSR1 1453/4885GLA 4334/4885TLR9 876/4885 |
| US-20160060229-A1 | N-HYDROXYLAMINO-BARBITURIC ACID DERIVATIVES | TNNT2, TNNI3, TNNC1 | NPSR1 985/4885GLA 2797/4885TLR9 4553/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.